AstraZeneca Faslodex survival data
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
AstraZeneca's breast cancer therapy Faslodex (fulvestrant) is not significantly different from the firm's Arimidex (anastrazole) in the first mature survival data available since approval. Median duration of survival was 27.4 months vs. 27.7 months, respectively. After a median follow-up of 27.2 months, 75% of Faslodex patients vs. 76% of Arimidex patients had died of any cause. The data, presented Dec. 5 at the San Antonio Breast Cancer Symposium, are based on two Phase III trials in a total of 851 postmenopausal women with advanced breast cancer with progression following antiestrogen treatment. AstraZeneca is currently enrolling patients in its 650-patient EFECT study (Evaluation of Faslodex vs. Exemestane Clinical Trial) to compare Faslodex to Pfizer's Aromasin in postmenopausal women with hormone receptor-positive metastatic breast cancer...
You may also be interested in...
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.
‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports
The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.